Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$20.79 USD
-0.56 (-2.62%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Cash flow Statements
Fiscal Year End for Catalyst Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 71.41 | 83.08 | 39.48 | 74.98 | 31.88 |
Depreciation/Amortization & Depletion | 32.88 | 1.24 | 0.48 | 0.89 | 0.30 |
Net Change from Assets/Liabilities | -37.32 | 13.73 | 5.02 | -4.12 | -1.39 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 76.63 | 18.00 | 15.38 | -26.71 | 3.82 |
Net Cash From Operating Activities | 143.60 | 116.05 | 60.37 | 45.03 | 34.61 |
Property & Equipment | -0.23 | -0.03 | -1.02 | -0.01 | -0.02 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -13.47 | 19.24 | -10.00 | -5.00 | 37.24 |
Other Investing Activities | -279.81 | -10.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -293.50 | 9.21 | -11.02 | -5.01 | 37.22 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.79 | 2.66 | -7.99 | 0.76 | 1.12 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -13.65 | -0.97 | -0.15 | -0.06 | 0.00 |
Net Cash from Financing Activities | -10.86 | 1.69 | -8.14 | 0.70 | 1.12 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -160.76 | 126.95 | 41.21 | 40.73 | 72.95 |
Cash at Beginning of Period | 298.40 | 171.45 | 130.24 | 89.51 | 16.56 |
Cash at End of Period | 137.64 | 298.40 | 171.45 | 130.24 | 89.51 |
Diluted Net EPS | 0.63 | 0.75 | 0.37 | 0.71 | 0.30 |
Fiscal Year End for Catalyst Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 64.07 | 23.28 | 71.41 | 36.57 | 67.33 |
Depreciation/Amortization & Depletion | 18.87 | 9.43 | 32.88 | 23.74 | 15.17 |
Net Change from Assets/Liabilities | 0.00 | -8.65 | -37.32 | -44.98 | -41.37 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 13.13 | 7.87 | 76.63 | 72.63 | 1.69 |
Net Cash From Operating Activities | 96.06 | 31.93 | 143.60 | 87.95 | 42.82 |
Property & Equipment | -0.21 | -0.20 | -0.23 | -0.14 | -0.07 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | -13.47 | -13.47 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | -279.81 | -241.58 | -162.29 |
Net Cash from Investing Activities | -0.21 | -0.20 | -293.50 | -255.18 | -162.37 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 144.55 | 142.52 | 2.79 | 2.10 | 1.89 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -2.35 | -1.47 | -13.65 | -12.29 | -1.95 |
Net Cash from Financing Activities | 142.21 | 141.05 | -10.86 | -10.19 | -0.07 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 238.06 | 172.78 | -160.76 | -177.42 | -119.61 |
Cash at Beginning of Period | 137.64 | 137.64 | 298.40 | 298.40 | 298.40 |
Cash at End of Period | 375.69 | 310.41 | 137.64 | 120.97 | 178.79 |
Diluted Net EPS | 0.33 | 0.19 | 0.33 | -0.29 | 0.33 |